| Title |
Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas
|
|---|---|
| Published in |
Journal of Neuro-Oncology, September 2008
|
| DOI | 10.1007/s11060-008-9699-x |
| Pubmed ID | |
| Authors |
Shin-Ichi Miyatake, Shinji Kawabata, Kunio Yokoyama, Toshihiko Kuroiwa, Hiroyuki Michiue, Yoshinori Sakurai, Hiroaki Kumada, Minoru Suzuki, Akira Maruhashi, Mitsunori Kirihata, Koji Ono |
| Abstract |
We have applied boron neutron capture therapy (BNCT) to malignant brain tumors. Here we evaluated the survival benefit of BNCT for recurrent malignant glioma (MG). Since 2002, we have treated 22 cases of recurrent MG with BNCT. Survival time was analyzed with special reference to recursive partitioning analysis (RPA) classification, by Carson et al. (J Clin Oncol 25:2601-2606, 2007). Median survival times (MSTs) after BNCT for all patients and for glioblastoma as on-study histology at recurrence was 10.8 months (n = 22; 95% CI, 7.3-12.8 months) and 9.6 months (n = 19; 95% CI, 6.9-11.4 months), respectively. In our study, MST for the high-risk RPA classes was 9.1 months (n = 11; 95% CI, 4.4-11.0 months). By contrast, the original journal data showed that the MST of the same RPA classes was 4.4 months (n = 129; 95% CI, 3.6-5.4 months). BNCT showed a survival benefit for recurrent MG, especially in the high-risk group. |
Mendeley readers
The data shown below were compiled from readership statistics for 65 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Croatia | 1 | 2% |
| Canada | 1 | 2% |
| Unknown | 63 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 18% |
| Student > Ph. D. Student | 10 | 15% |
| Student > Doctoral Student | 7 | 11% |
| Student > Master | 5 | 8% |
| Student > Bachelor | 4 | 6% |
| Other | 12 | 18% |
| Unknown | 15 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 26% |
| Chemistry | 8 | 12% |
| Engineering | 8 | 12% |
| Neuroscience | 4 | 6% |
| Physics and Astronomy | 3 | 5% |
| Other | 6 | 9% |
| Unknown | 19 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 July 2013.
All research outputs
#7,454,951
of 22,790,780 outputs
Outputs from Journal of Neuro-Oncology
#1,041
of 2,967 outputs
Outputs of similar age
#31,580
of 87,868 outputs
Outputs of similar age from Journal of Neuro-Oncology
#8
of 10 outputs
Altmetric has tracked 22,790,780 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,967 research outputs from this source. They receive a mean Attention Score of 4.2. This one is in the 48th percentile – i.e., 48% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 87,868 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.